<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:22:39Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9841458" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9841458</identifier>
        <datestamp>2023-01-17</datestamp>
        <setSpec>sageopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Chronic Illn</journal-id>
              <journal-id journal-id-type="iso-abbrev">Chronic Illn</journal-id>
              <journal-id journal-id-type="publisher-id">CHI</journal-id>
              <journal-id journal-id-type="hwp">spchi</journal-id>
              <journal-title-group>
                <journal-title>Chronic Illness</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1742-3953</issn>
              <issn pub-type="epub">1745-9206</issn>
              <publisher>
                <publisher-name>SAGE Publications</publisher-name>
                <publisher-loc>Sage UK: London, England</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9841458</article-id>
              <article-id pub-id-type="pmcid">PMC9841458</article-id>
              <article-id pub-id-type="pmc-uid">9841458</article-id>
              <article-id pub-id-type="pmid">34787471</article-id>
              <article-id pub-id-type="pmid">34787471</article-id>
              <article-id pub-id-type="doi">10.1177/17423953211060253</article-id>
              <article-id pub-id-type="publisher-id">10.1177_17423953211060253</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Burden of cancer trial participation: A qualitative sub-study of the
INTERIM feasibility RCT</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5510-1103</contrib-id>
                  <name>
                    <surname>Nwolise</surname>
                    <given-names>Chidiebere</given-names>
                  </name>
                  <xref rid="aff1-17423953211060253" ref-type="aff">1</xref>
                  <xref rid="aff2-17423953211060253" ref-type="aff">2</xref>
                  <xref rid="corresp1-17423953211060253" ref-type="corresp"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Corrie</surname>
                    <given-names>Pippa</given-names>
                  </name>
                  <xref rid="aff3-17423953211060253" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fitzpatrick</surname>
                    <given-names>Ray</given-names>
                  </name>
                  <xref rid="aff1-17423953211060253" ref-type="aff">1</xref>
                  <xref rid="aff2-17423953211060253" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gupta</surname>
                    <given-names>Avinash</given-names>
                  </name>
                  <xref rid="aff4-17423953211060253" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3692-0779</contrib-id>
                  <name>
                    <surname>Jenkinson</surname>
                    <given-names>Crispin</given-names>
                  </name>
                  <xref rid="aff1-17423953211060253" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Middleton</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <xref rid="aff5-17423953211060253" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9695-5412</contrib-id>
                  <name>
                    <surname>Matin</surname>
                    <given-names>Rubeta</given-names>
                  </name>
                  <xref rid="aff6-17423953211060253" ref-type="aff">6</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1-17423953211060253"><label>1</label>Health Services Research Unit, Nuffield Department of Population
Health, <institution-wrap><institution-id institution-id-type="Ringgold">6396</institution-id><institution content-type="university">University of Oxford</institution></institution-wrap>, Oxford, UK</aff>
              <aff id="aff2-17423953211060253"><label>2</label>National Institute for Health Research (NIHR) Applied Research
Collaboration Oxford, Oxford, UK</aff>
              <aff id="aff3-17423953211060253"><label>3</label><institution-wrap><institution-id institution-id-type="Ringgold">2153</institution-id><institution content-type="university">Cambridge Cancer Centre</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="Ringgold">2153</institution-id><institution content-type="university">Cambridge University Hospitals NHS
Foundation Trust (Addenbrooke's Hospital)</institution></institution-wrap>, Cambridge, UK</aff>
              <aff id="aff4-17423953211060253"><label>4</label><institution-wrap><institution-id institution-id-type="Ringgold">5294</institution-id><institution content-type="university">The Christie NHS Foundation
Trust</institution></institution-wrap>, Manchester, UK</aff>
              <aff id="aff5-17423953211060253"><label>5</label><institution-wrap><institution-id institution-id-type="Ringgold">3533</institution-id><institution content-type="university">University of Oxford Department of
Oncology</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="Ringgold">3533</institution-id><institution content-type="university">Cancer Research UK Oxford
Centre</institution></institution-wrap>, Oxford, UK</aff>
              <aff id="aff6-17423953211060253"><label>6</label>Dermatology Department, <institution-wrap><institution-id institution-id-type="Ringgold">99060</institution-id><institution content-type="university">Churchill Hospital</institution></institution-wrap>, Oxford, UK</aff>
              <author-notes>
                <corresp id="corresp1-17423953211060253">Chidiebere Nwolise, Health Services
Research Unit, Nuffield Department of Population Health, University of Oxford,
L1/16 Richard Doll Building, Old Road Campus, Headington, Oxford OX3 7LF, UK.
Email: <email>chidiebere.nwolise@ndph.ox.ac.uk</email>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>17</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <volume>19</volume>
              <issue>1</issue>
              <fpage>81</fpage>
              <lpage>94</lpage>
              <history>
                <date date-type="received">
                  <day>23</day>
                  <month>10</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>23</day>
                  <month>10</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2021</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <sec>
                  <title>Objective</title>
                  <p>A qualitative sub-study was carried out within a larger phase II feasibility
trial, to identify and describe the burden experienced by advanced melanoma
patients participating in a clinical trial and the factors affecting their
capacity to cope with the burden.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>Semi-structured interviews were conducted with fourteen patients with
advanced melanoma recruited from National Health Service hospitals in the
United Kingdom. Qualitative analysis was undertaken using a framework
analysis approach. Normalisation process theory was applied to the concept
of research participation burden in order to interpret and categorise
findings.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Burdens of participation were identified as arising from making sense of the
trial and treatment; arranging transport, appointment and prescriptions;
enacting management strategies and enduring side effects; reflecting on
trial documents and treatment efficacy, and emotional and mental effects of
randomisation and treatment side effects. Factors reported as influencing
capacity include personal attributes and skills, physical and cognitive
abilities and support network.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p>This is the first study to highlight the substantial burden faced by patients
with advanced melanoma in a clinical trial and factors that may lessen or
worsen the burden. Consideration of identified burdens during trial design
and execution will reduce the burden experienced by research
participants.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Research burden</kwd>
                <kwd>patient capacity</kwd>
                <kwd>treatment burden</kwd>
                <kwd>qualitative</kwd>
                <kwd>cancer trial participation</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="award1-17423953211060253">
                  <funding-source id="funding1-17423953211060253">
                    <institution-wrap>
                      <institution>National Institute for Health Research (NIHR) Research for
Patient Benefit (RfPB)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding1-17423953211060253">Grant Reference Number:
PB-PG-0815-20048</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>typesetter</meta-name>
                  <meta-value>ts19</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="section1-17423953211060253">
              <title>Introduction</title>
              <p>Melanoma is a life-threatening skin cancer with a high incidence rate and accounts
for 4% of all new cancer cases.<sup><xref rid="bibr1-17423953211060253" ref-type="bibr">1</xref>,<xref rid="bibr2-17423953211060253" ref-type="bibr">2</xref></sup> Globally, incidence rates of
melanoma rose by 44% between 2008 and 2018,<sup><xref rid="bibr3-17423953211060253" ref-type="bibr">3</xref></sup> with deaths increasing by 32%.
Australia, New Zealand and the United Kingdom (UK) are among the countries with the
highest incidence rates.<sup><xref rid="bibr4-17423953211060253" ref-type="bibr">4</xref></sup> Melanoma is an aggressive malignancy that tends to
metastasize beyond its primary site. The introduction of oral targeted combination
therapies that target the BRAF (v-raf murine sarcoma viral oncogene homolog B1)
mutations has improved overall survival rates.<sup><xref rid="bibr5-17423953211060253" ref-type="bibr">5</xref></sup> These targeted therapies incur
significant toxicity and this can limit their efficacy. Moreover, patients assume
the responsibility for understanding the medication regimen and determining how to
best integrate the treatment and treatment-related side effects into their daily
lives.<sup><xref rid="bibr6-17423953211060253" ref-type="bibr">6</xref>,<xref rid="bibr7-17423953211060253" ref-type="bibr">7</xref></sup>
Consequently, many patients will experience burden both from their illness and from
the demanding treatment regimen. The increased emphasis on self-management in cancer
patients, deemed necessary to improve outcomes and reduce costs, shifts the
long-term management of ill-health from clinicians to patients;<sup><xref rid="bibr6-17423953211060253" ref-type="bibr">6</xref>–<xref rid="bibr6-17423953211060253" ref-type="bibr">9</xref></sup> yet the treatment burden that
patients experience is not well understood.<sup><xref rid="bibr6-17423953211060253" ref-type="bibr">6</xref>,<xref rid="bibr8-17423953211060253" ref-type="bibr">8</xref></sup></p>
              <p>Treatment burden is the healthcare workload (tasks recommended by clinicians to
improve health status, e.g., attending medical appointments, managing complex
medication, diet and exercise regimens) experienced by patients with chronic
conditions and the impact this has on behavioural, cognitive, physical and
psychological well-being.<sup><xref rid="bibr6-17423953211060253" ref-type="bibr">6</xref>–<xref rid="bibr6-17423953211060253" ref-type="bibr">10</xref></sup> Patients who struggle with complex and demanding treatment
regimens often experience adverse outcomes including poor self-management, adherence
to medication therapies and quality of life (QOL), leading to increased
hospitalisation rates, healthcare costs and mortality.<sup><xref rid="bibr11-17423953211060253" ref-type="bibr">11</xref></sup> The medical approach to poor
outcomes which is to intensify treatment may inadvertently increase treatment burden
as already burdened patients are asked to do more by their clinicians.<sup><xref rid="bibr11-17423953211060253" ref-type="bibr">11</xref></sup> Treatment
burden for people with advanced melanoma on oral therapies remains
under-researched.<sup><xref rid="bibr6-17423953211060253" ref-type="bibr">6</xref></sup> Research participation will exacerbate basic treatment
burden as patients face the additional burden of increased travel, completing
questionnaires and undergoing supplementary procedures specific to a
trial.<sup><xref rid="bibr12-17423953211060253" ref-type="bibr">12</xref></sup> Evidently, research participants in clinical trials experience
both treatment and trial burden; underscoring the need to fully explore their
experiences.<sup><xref rid="bibr12-17423953211060253" ref-type="bibr">12</xref>,<xref rid="bibr13-17423953211060253" ref-type="bibr">13</xref></sup></p>
              <p>Capacity is the abilities and resources that patients can mobilise to manage and cope
with the demands of healthcare and life that if limited, impacts the ability of
individuals to self-manage.<sup><xref rid="bibr7-17423953211060253" ref-type="bibr">7</xref></sup> Patient capacity determines whether the combination of
participating in a clinical trial in conjunction with the burden of taking a therapy
will be perceived as potentially unmanageable or excessively burdensome. The ability
to follow treatment regimens is affected by several factors including social
support, financial constraints, personality and cognitive functioning.<sup><xref rid="bibr7-17423953211060253" ref-type="bibr">7</xref>,<xref rid="bibr8-17423953211060253" ref-type="bibr">8</xref></sup> Hence, patients experiencing
the same level of healthcare demands may cope very differently due to variation in
capacity.<sup><xref rid="bibr8-17423953211060253" ref-type="bibr">8</xref>,<xref rid="bibr14-17423953211060253" ref-type="bibr">14</xref></sup> Patients with advanced cancer often present with severe
ill-health when oral therapy is prescribed,<sup><xref rid="bibr6-17423953211060253" ref-type="bibr">6</xref></sup> and treatment side effects such
as pyrexia and fatigue which impact wellbeing and QOL are common.<sup><xref rid="bibr15-17423953211060253" ref-type="bibr">15</xref></sup> However, the
impact of treatment side effects on QOL is under-estimated by clinicians,<sup><xref rid="bibr16-17423953211060253" ref-type="bibr">16</xref>–<xref rid="bibr16-17423953211060253" ref-type="bibr">18</xref></sup> and although
treatment burden and capacity in patients with chronic conditions is gaining
recognition,<sup><xref rid="bibr9-17423953211060253" ref-type="bibr">9</xref>,<xref rid="bibr11-17423953211060253" ref-type="bibr">11</xref>–<xref rid="bibr11-17423953211060253" ref-type="bibr">14</xref></sup> little is known about the experiences of patients with advanced
melanoma taking part in a clinical trial.</p>
              <p>Despite improving outcomes, continuous daily dosing is associated with several
challenges including treatment resistance with a median progression-free survival of
12 months, treatment compliance and QOL. Hence, intermittent dosing may help delay
onset of disease progression, manage drug-induced toxicity and improve tolerability.
INTERIM (INTERmittent vs. continuous dosing of oral targeted combination therapy in
patients with BRAFV600 mutant stage 3 unresectable or stage 4 metastatic melanoma)
was the first randomised phase II feasibility trial to deliver intermittent dosing
of the oral targeted combination therapy alongside standard care (continuous
dosing), and examine QOL, clinical efficacy, safety, time to treatment failure,
overall survival and toxicity. In addition to trial outcomes, patient experiences
were explored to gain perspectives about the intervention and trial participation
that were not otherwise evaluable through quantitative measures. Qualitative
research provides insight into areas of enquiry with little baseline understanding,
explores experiences of sub-groups, enhances trial findings and allows more complex
phenomena to be explored in detail.<sup><xref rid="bibr19-17423953211060253" ref-type="bibr">19</xref></sup> Therefore, the aim of this
qualitative sub-study was to identify and describe the burden of participating in a
clinical trial whilst living with advanced melanoma, and the factors affecting
capacity to cope with this burden.</p>
            </sec>
            <sec sec-type="methods" id="section2-17423953211060253">
              <title>Methods</title>
              <p>A qualitative sub-study exploring the views and experiences of patients with advanced
melanoma was undertaken as part of a phase II randomised controlled trial (RCT)
(trial registration number: 2016-005228-27).<sup><xref rid="bibr20-17423953211060253" ref-type="bibr">20</xref></sup> Briefly, between December
2017 and March 2020, 79 patients with BRAFV600 mutant stage 3 unresectable or stage
4 metastatic melanoma, due to start a course of targeted oral combination therapy
(dabrafenib and trametinib treatment) were recruited from 25 participating UK
National Health Service (NHS) hospitals and enrolled in the parent RCT
(intervention = 40; standard care = 39). Three participants were lost to follow-up
and 24 died during the study. This article, prepared using the consolidated criteria
for reporting qualitative research (COREQ),<sup><xref rid="bibr21-17423953211060253" ref-type="bibr">21</xref></sup> reports solely on qualitative
study findings. Favourable ethical opinion was obtained from Cambridge South
Research Ethics Committee [17/EE/0340].</p>
              <sec id="section2A-17423953211060253">
                <title>Intervention</title>
                <p>Intervention participants received intermittent dosing of the oral targeted
combination therapy and standard care participants, continuous dosing (<ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17423953211060253" ext-link-type="uri">Online Appendix 1</ext-link>).</p>
              </sec>
              <sec id="section2B-17423953211060253">
                <title>Sampling, recruitment, and consent</title>
                <p>Study personnel at each site invited participants (face-to-face or via telephone)
who had been in the RCT for 6 months, to take part in a semi-structured
interview. Convenience sampling was used to recruit intervention and standard
care participants in order to understand the perspectives of patients in both
arms of the trial. Participants met the following inclusion criteria: age ≥ 18
years; histologically or cytologically confirmed mutant stage 3 or stage 4
melanoma; predicted life expectancy ˃12 weeks; adequate renal, liver and bone
marrow function; willingness to comply with scheduled visits, treatment, lab
tests and completion of trial procedures described in the protocol. Of the 16
participants who agreed to be interviewed, two could not be contacted despite
several attempts and 14 were interviewed.</p>
              </sec>
              <sec id="section2C-17423953211060253">
                <title>Data collection</title>
                <p>Participants received postal study information sheets, explaining the research,
and consent forms along with a pre-paid envelope (for returning signed consent
forms). Prior to data collection, the researcher [CN] also contacted
participants to introduce herself, clarify the reasons for the study and answer
questions. Written consent was obtained prior to data collection. Telephone
interviews, guided by an interview schedule informed by the literature<sup><xref rid="bibr13-17423953211060253" ref-type="bibr">13</xref>,<xref rid="bibr22-17423953211060253" ref-type="bibr">22</xref>,<xref rid="bibr23-17423953211060253" ref-type="bibr">23</xref></sup> and
developed by the multi-disciplinary study team, were conducted by one researcher
[CN]. The interview schedule was piloted with two non-participating cancer
patients and revised (<ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17423953211060253" ext-link-type="uri">Online Appendix 2</ext-link>). The average time for interviews
(<italic toggle="yes">n</italic> = 14) was 36 min, with a range between 17 and 60 min.
Data collection took place between July 2019 and June 2020.</p>
              </sec>
              <sec id="section2D-17423953211060253">
                <title>Data analysis</title>
                <p>The framework method was used.<sup><xref rid="bibr24-17423953211060253" ref-type="bibr">24</xref></sup> All interviews were
audio-recorded, transcribed, anonymised, checked for accuracy and imported into
NVivo 12 software to aid analysis. Themes were constructed deductively using
pre-defined themes within the Normalisation Process Theory (NPT), patient
capacity literature<sup><xref rid="bibr8-17423953211060253" ref-type="bibr">8</xref>,<xref rid="bibr13-17423953211060253" ref-type="bibr">13</xref></sup> and inductively by identifying additional themes within the
data. The procedure for analysis included: transcription, familiarisation with
the interview, coding, developing and applying analytical framework, charting
data into the framework matrix and interpreting the data. Two members of the
research team [CN, RF] independently coded and analysed the transcripts to
identify themes and ensure inter-rater reliability; variations in coding were
discussed and agreement reached on designated themes. Thereafter, themes were
discussed and agreed with co-authors [CJ and RM]. Themes from all interviews
were categorised into those that described burden (facilitated by NPT) and
patient capacity.</p>
                <sec id="section2D1-17423953211060253">
                  <title>Conceptual framework</title>
                  <p>Normalisation Process Theory (NPT) is an analytic framework for understanding
the organisation and implementation of tasks such that they become routine
and incorporated into everyday practice.<sup><xref rid="bibr25-17423953211060253" ref-type="bibr">25</xref></sup> Although NPT has
often been used to understand complex and technological interventions, it is
also being increasingly used to conceptualise the tasks or work carried out
by patients to manage chronic illnesses.<sup><xref rid="bibr11-17423953211060253" ref-type="bibr">11</xref>,<xref rid="bibr13-17423953211060253" ref-type="bibr">13</xref>,<xref rid="bibr26-17423953211060253" ref-type="bibr">26</xref></sup> NPT encompasses four
distinct components (<xref rid="table1-17423953211060253" ref-type="table">Table 1</xref>) which have been used previously to describe the burden
experienced by patients managing a chronic illness.<sup><xref rid="bibr11-17423953211060253" ref-type="bibr">11</xref>,<xref rid="bibr25-17423953211060253" ref-type="bibr">25</xref></sup> NPT
was applied to the data in order to conceptualise the work undertaken by
patients with advanced melanoma taking part in a clinical trial.</p>
                  <table-wrap position="float" id="table1-17423953211060253">
                    <label>Table 1.</label>
                    <caption>
                      <p>Components of NPT.</p>
                    </caption>
                    <alternatives>
                      <graphic xlink:href="10.1177_17423953211060253-table1" position="float"/>
                      <table frame="hsides" rules="groups">
                        <colgroup span="1">
                          <col align="left" span="1"/>
                          <col align="center" span="1"/>
                        </colgroup>
                        <thead>
                          <tr>
                            <th rowspan="1" colspan="1">Component</th>
                            <th rowspan="1" colspan="1">Definition</th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td rowspan="1" colspan="1">Sense-making work</td>
                            <td rowspan="1" colspan="1">Learning about disease diagnosis, treatments, and their
consequences as well as reading trial paperwork and
seeking information on trial processes.</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Relationship work</td>
                            <td rowspan="1" colspan="1">Engaging with others for help and support, arranging
medical care and mobilising resources to arrange support
or help with transportation, prescriptions, and other
essential services.</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Enacting work</td>
                            <td rowspan="1" colspan="1">Implementing the self-management tasks and adapting
daily activities to accommodate the illness; completing
trial questionnaires and attending hospital
appointments.</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Appraisal work</td>
                            <td rowspan="1" colspan="1">Refining and adjusting the treatment regimen as
necessary and assessing whether to continue or change
current management plans. Reflecting on trial documents
including questionnaires and decision to take part in
trial.</td>
                          </tr>
                        </tbody>
                      </table>
                    </alternatives>
                  </table-wrap>
                </sec>
              </sec>
              <sec id="section2E-17423953211060253">
                <title>Findings</title>
                <sec id="section2E1-17423953211060253">
                  <title>Demographics</title>
                  <p>Demographic characteristics of the 14 participants (intermittent,
<italic toggle="yes">n</italic> = 7 and continuous, <italic toggle="yes">n</italic> = 7) are shown
in <xref rid="table2-17423953211060253" ref-type="table">Table 2</xref>.</p>
                  <table-wrap position="float" id="table2-17423953211060253">
                    <label>Table 2.</label>
                    <caption>
                      <p>Demographic detail of study participants.</p>
                    </caption>
                    <alternatives>
                      <graphic xlink:href="10.1177_17423953211060253-table2" position="float"/>
                      <table frame="hsides" rules="groups">
                        <colgroup span="1">
                          <col align="left" span="1"/>
                          <col align="center" span="1"/>
                          <col align="center" span="1"/>
                          <col align="center" span="1"/>
                          <col align="center" span="1"/>
                          <col align="center" span="1"/>
                        </colgroup>
                        <thead>
                          <tr>
                            <th rowspan="1" colspan="1">No</th>
                            <th rowspan="1" colspan="1">Identifier</th>
                            <th rowspan="1" colspan="1">Gender</th>
                            <th rowspan="1" colspan="1">Geographical location</th>
                            <th rowspan="1" colspan="1">Age (years)</th>
                            <th rowspan="1" colspan="1">Intervention arm</th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td rowspan="1" colspan="1">1.</td>
                            <td rowspan="1" colspan="1">P1</td>
                            <td rowspan="1" colspan="1">Male</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">78</td>
                            <td rowspan="1" colspan="1">Continuous</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">2.</td>
                            <td rowspan="1" colspan="1">P2</td>
                            <td rowspan="1" colspan="1">Female</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">50</td>
                            <td rowspan="1" colspan="1">Continuous</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">3.</td>
                            <td rowspan="1" colspan="1">P3</td>
                            <td rowspan="1" colspan="1">Male</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">70</td>
                            <td rowspan="1" colspan="1">Intermittent</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">4.</td>
                            <td rowspan="1" colspan="1">P4</td>
                            <td rowspan="1" colspan="1">Female</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">70</td>
                            <td rowspan="1" colspan="1">Intermittent</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">5.</td>
                            <td rowspan="1" colspan="1">P5</td>
                            <td rowspan="1" colspan="1">Male</td>
                            <td rowspan="1" colspan="1">Scotland</td>
                            <td rowspan="1" colspan="1">49</td>
                            <td rowspan="1" colspan="1">Continuous</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">6.</td>
                            <td rowspan="1" colspan="1">P6</td>
                            <td rowspan="1" colspan="1">Male</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">57</td>
                            <td rowspan="1" colspan="1">Continuous</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">7.</td>
                            <td rowspan="1" colspan="1">P7</td>
                            <td rowspan="1" colspan="1">Male</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">47</td>
                            <td rowspan="1" colspan="1">Continuous</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">8.</td>
                            <td rowspan="1" colspan="1">P8</td>
                            <td rowspan="1" colspan="1">Female</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">Not available</td>
                            <td rowspan="1" colspan="1">Intermittent</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">9.</td>
                            <td rowspan="1" colspan="1">P9</td>
                            <td rowspan="1" colspan="1">Female</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">57</td>
                            <td rowspan="1" colspan="1">Intermittent</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">10.</td>
                            <td rowspan="1" colspan="1">P10</td>
                            <td rowspan="1" colspan="1">Male</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">67</td>
                            <td rowspan="1" colspan="1">Continuous</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">11.</td>
                            <td rowspan="1" colspan="1">P11</td>
                            <td rowspan="1" colspan="1">Male</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">80</td>
                            <td rowspan="1" colspan="1">Intermittent</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">12.</td>
                            <td rowspan="1" colspan="1">P12</td>
                            <td rowspan="1" colspan="1">Female</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">81</td>
                            <td rowspan="1" colspan="1">Intermittent</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">13.</td>
                            <td rowspan="1" colspan="1">P13</td>
                            <td rowspan="1" colspan="1">Female</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">62</td>
                            <td rowspan="1" colspan="1">Continuous</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">14.</td>
                            <td rowspan="1" colspan="1">P14</td>
                            <td rowspan="1" colspan="1">Female</td>
                            <td rowspan="1" colspan="1">England</td>
                            <td rowspan="1" colspan="1">49</td>
                            <td rowspan="1" colspan="1">Intermittent</td>
                          </tr>
                        </tbody>
                      </table>
                    </alternatives>
                  </table-wrap>
                </sec>
                <sec id="section2E2-17423953211060253">
                  <title>Themes</title>
                  <p>Two major themes and a number of sub-themes emerged from the interview data
(<xref rid="table3-17423953211060253" ref-type="table">Table 3</xref>).
These themes and their sub-themes are described below, along with
representative quotes [with additional quotes appearing in <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17423953211060253" ext-link-type="uri">supplementary data file 1</ext-link>]. Excerpts from the transcripts
are referenced using P, followed by a number for each participant and the
treatment arm, that is, standard care (SC) or intervention (I).</p>
                  <table-wrap position="float" id="table3-17423953211060253">
                    <label>Table 3.</label>
                    <caption>
                      <p>Themes and sub-themes.</p>
                    </caption>
                    <alternatives>
                      <graphic xlink:href="10.1177_17423953211060253-table3" position="float"/>
                      <table frame="hsides" rules="groups">
                        <colgroup span="1">
                          <col align="left" span="1"/>
                          <col align="center" span="1"/>
                        </colgroup>
                        <thead>
                          <tr>
                            <th rowspan="1" colspan="1">Main themes</th>
                            <th rowspan="1" colspan="1">Sub-themes</th>
                          </tr>
                        </thead>
                        <tbody>
                          <tr>
                            <td rowspan="5" colspan="1">Burden of being a research participant in a
clinical trial</td>
                            <td rowspan="1" colspan="1">Sense-making work</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Relationship work</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Enacting work</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Appraisal work</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Psychological burden</td>
                          </tr>
                          <tr>
                            <td rowspan="7" colspan="1">Factors affecting patient capacity</td>
                            <td rowspan="1" colspan="1">Altruistic motivation</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Emotion-focused coping</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Personal attributes and skills</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Physical and cognitive abilities</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Positive reinforcement and feedback</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Financial status</td>
                          </tr>
                          <tr>
                            <td rowspan="1" colspan="1">Support network</td>
                          </tr>
                        </tbody>
                      </table>
                    </alternatives>
                  </table-wrap>
                </sec>
              </sec>
              <sec id="section2F-17423953211060253">
                <title>Burden of being a research participant in a clinical trial</title>
                <p>The tasks carried out by patients to manage their illness (e.g., taking
medications, reading information leaflets, arranging transportation to attend
hospital appointments, making lifestyle changes) and the personal impacts of
trial participation, were discussed by participants.</p>
                <sec id="section2F1-17423953211060253">
                  <title>Sense-making work</title>
                  <p>All participants described their diagnosis as life-changing and previous
cancer treatments as torturous. However, despite undergoing and experiencing
adverse effects of several procedures including surgery, radiotherapy and
immunotherapy, they learned that their disease had become advanced following
unfavourable scan results. The combined targeted oral therapy was
subsequently prescribed to reduce the likelihood of further disease
progression. They reported that clinicians explained the challenges
associated with continuous administration of the drug (standard care),
however, it was unclear whether equipoise was sufficiently explained.</p>
                  <p>Participants reported that they were provided with verbal and written
information which they described as informative, and noted being given
sufficient time to make an informed decision. Many participants acknowledged
not having a good understanding of melanoma treatment and management at the
outset but invested time and effort into understanding the treatment and
trial by reading trial documents and asking questions.<disp-quote><p>I basically asked how it would work … just to have the whole process
explained to me because it is quite complicated … It did take
getting my head round it … what to expect and all that sort of thing
… initially, I knew nothing about it. [P8, I]</p></disp-quote></p>
                  <p>Some routinely used the internet to look up health information and through
personal research, enhanced their understanding of the treatment.</p>
                  <p>Despite the reported level of written and oral information provided
beforehand, some participants acknowledged that they did not fully
understand the information provided which subsequently led to
misconceptions; for example, erroneously perceiving the treatment as
curative rather than life-extending. Important RCT concepts such as
randomisation were also difficult for some to understand and/or accept.<disp-quote><p>[Randomisation] was quite an unusual aspect to deal with certainly in
terms of the fact that we were dealing with such an important
treatment for myself … I was keen to try and understand … was every
patient treated completely randomly? Or was every second patient
treated conversely to the first patient? [P5,
SC]</p></disp-quote></p>
                  <p>Additionally, participants felt that they had not received comprehensive
information regarding treatment side effects.</p>
                </sec>
              </sec>
              <sec id="section2G-17423953211060253">
                <title>Relationship work</title>
                <p>Participants engaged with clinicians, friends and family with regard to the
disease and its management to enable them to provide support. They reported good
relationships with the trial clinicians who they consulted frequently during the
trial. Those who contacted clinicians by phone either received advice over the
phone or organised a clinic appointment. Participants spoke highly of the trial
clinicians and mentioned the exceptional care received and the approachability
of the research nurses.<disp-quote><p>Dr [name] at [city], he organised everything extremely quickly in
conjunction with [hospital], and the service and the care I’ve got was
fantastic … well, I couldn't have got any better if I’d have gone
private, to be quite honest; it was excellent. [P7,
SC]</p></disp-quote></p>
                <p>Participants felt that seeing the same clinicians at each consultation was
important and invaluable to their experience. They highlighted that whereas
continuity of care was often lacking in secondary care, being in the trial made
it possible for participants to be looked after by the same nurse(s), with whom
they had developed a relationship.</p>
                <p>Participants were also involved in arranging hospital appointments,
transportation and prescriptions. Most patients relied on others, mostly family
members, to help out with transport to appointments. Some also spent time
liaising with and arranging help from social services and cancer charities.
There were very few reports of unsatisfactory encounters during the trial that
fell below participants’ expectations although several participants complained
about the delay with the prescription service that resulted in more time being
spent in hospital than necessary.</p>
              </sec>
              <sec id="section2H-17423953211060253">
                <title>Enacting work</title>
                <p>Participants described the logistic and practical day-to-day activities they had
to undertake in order to adhere to treatments and maintain their health. They
highlighted the considerable amount of work and time involved in attending
multiple hospital appointments, including consultations, questionnaire
completion, blood tests and scans.<disp-quote><p>The main problem is all the hospital appointments. It's getting there all
the time that they want you there … that's the only thing that gets me
down a bit. [P1, SC]</p></disp-quote></p>
                <p>However, some felt that this level of monitoring was essential given the advanced
stage of the disease and potency of the oral therapy.</p>
                <p>Adhering to treatment consumed an immense amount of time, and working out the
strict timing of the medication proved particularly difficult for participants.
Hence, medication non-compliance occurred despite strategies to prevent it, that
is, using alarm clocks and log books/diaries. Additionally, enduring and
managing treatment side effects consumed the largest proportion of participant's
time and energy. All participants experienced a number of treatment side effects
that affected their physical and mental wellbeing, including pyrexia, flu-like
symptoms, vomiting, syncope and pustular eruptions.<disp-quote><p>One morning I collapsed and then I got the shakes… My blood pressure went
very low. I got out of bed and then I fell in the bathroom … and my wife
couldn't get me out and then they took me into [hospital] and they kept
me in for about five days. [P12, I]</p></disp-quote></p>
                <p>Most participants were taking a variety of medications to control treatment side
effects including proton pump inhibitors, morphine and steroids, which also had
side effects which they endured, for example, insomnia. Participants stressed
that they were solely responsible for self-managing their disease(s) and
treatment, and felt that the onus was on patients to follow clinicians’
directives. Most reported initially relying on clinicians for advice but had
since developed confidence to self-manage their side effects.</p>
              </sec>
              <sec id="section2I-17423953211060253">
                <title>Appraisal work</title>
                <p>Much effort was also expended on trying to incorporate the treatment and side
effects into daily lives, and participants independently altered medication
regimens to fit in with their daily activities. In addition, participants spent
time assessing management plans either with the help of clinicians or
independently, hence, those who suffered severe adverse effects were advised to
either introduce a break in the medication regimen or continue on a reduced dose
indefinitely. Participants on the reduced dose experienced improved QOL.<disp-quote><p>I’ve noticed a difference now on a lower dose that I’m not that tired …
As for the [side effects], they’ve really kind of dissipated … at the
moment the medication's suiting me and keeping the cancer at bay, and my
quality of life isn't being affected. [P3, I]</p></disp-quote></p>
                <p>Participants also reported reflecting on self-management practices and treatment
efficacy. Participants were motivated to persevere with current treatment
despite experiencing side effects as they saw noticeable improvements in the
extent of their disease.</p>
                <p>Overall, participants were satisfied with the efficacy of the targeted therapy.
Participants also attended monthly follow-up visits, self-completed
questionnaires every 3 months, and reported all other side effects as they arose
by completing questionnaires. Participants felt that the questionnaires were
useful because they assessed both physical and psychological effects, and
enabled participants to reflect on their progress and wellbeing. However, some
felt that it did not fully capture the psychological issues participants
experienced during the trial.</p>
                <p>Participants also reflected on and reported being satisfied with the overall
conduct of the trial. However, they suggested that in future, due to the potency
of the drug, the current dosage should be more closely monitored or reduced in
order to prevent severe adverse reactions.</p>
              </sec>
              <sec id="section2J-17423953211060253">
                <title>Psychological burden</title>
                <p>The emotional and mental effects of trial and treatment featured prominently and
were frequently mentioned by participants. For example, some reported feeling
fearful and anxious at the possibility of not meeting the trial eligibility
criteria. They also reported experiencing low mood, sadness and anxiety during
the trial. In addition, they ascribed the strong negative emotions they felt to
the targeted therapy.<disp-quote><p>The first few weeks it made me feel really aggressive and really quite
angry … I’ve never really experienced that amount of aggression and
anger before. [P7, SC]</p></disp-quote></p>
                <p>Given the severity of side effects, many participants reported spending time
gauging their physical and mental limitations and adjusting their day
accordingly. They found carrying out daily activities very difficult as it
demanded more energy than they could muster, leading to feelings of
frustration.</p>
                <p>Preference for the intermittent arm led to dissatisfaction. Despite progress made
during the trial, risk of further disease progression caused distress and
anxiety. </p>
              </sec>
              <sec id="section2K-17423953211060253">
                <title>Factors affecting patient capacity</title>
                <p>Factors that could enhance or reduce patient capacity to manage health problems
were described by participants.</p>
              </sec>
              <sec id="section2L-17423953211060253">
                <title>Altruistic motivation</title>
                <p>Taking part in research in order to benefit future patients and medical science
helped to create the feel-good factor and made enduring the burden and workload
of participating in the trial worthwhile. Participants were hopeful that lessons
learned from their experiences of the treatment, particularly adverse treatment
effects, would be applied to future research and improve understanding of the
effects of the targeted therapy.<disp-quote><p>They’re very keen, the clinical trial nurse, to record things that have
affected you during this trial. And I think that's obviously a good
thing … for the fact that it's going to be reported and looked at and
used in the future for other people. [P3, I]</p></disp-quote></p>
              </sec>
              <sec id="section2M-17423953211060253">
                <title>Personal attributes and skills</title>
                <p>Personality impacted on how patients managed their health and perceived their
care. Characteristics such as resilience, self-efficacy and self-determination
enabled participants to find the motivation and inner strength to keep taking
prescribed medication, enduring side effects and undertaking research activities.<disp-quote><p>I just dealt with it … I’m a pretty robust person in the form of whatever
comes my way I just deal with it … I’m quite resilient and able to cope
with a lot of things. [P7, SC]</p></disp-quote></p>
                <p>Some participants also used social comparison, that is, comparing themselves to
other people, to convince themselves that their burden was not so much that it
could not be managed.</p>
              </sec>
              <sec id="section2N-17423953211060253">
                <title>Emotion-focused coping</title>
                <p>Participants reported several strategies used to manage the negative emotions
associated with treatment and trial burden, for example, focusing on other life
priorities and carrying on with their everyday life.<disp-quote><p>I get fatigue and breathlessness, but … I’ve not changed my lifestyle … I
go out with my friends every weekend; I still go dancing … well, I’m
going to do that until I can't do it … it's the only way to be. I’m not
going to sit here and shrivel up. [P9, I]</p></disp-quote></p>
                <p>Some focused their energy on work, family interactions, outdoor and leisure
activities such as exercising and socialising to keep their spirits up and to
avoid ruminating on their disease. Participants also reported using the
favourable response to treatment as motivation to persevere.</p>
              </sec>
              <sec id="section2O-17423953211060253">
                <title>Positive reinforcement and feedback</title>
                <p>Participants felt that receiving frequent progress reports and/or feedback whilst
the study was ongoing, would generate enthusiasm, boost morale and encourage
active participation in the study. Highlighting and discussing the progress
participants have made was deemed crucial for patients with advanced disease, as
this would encourage adherence to treatment and endurance of the adverse effects.<disp-quote><p>Information is all one way from us to the trial … I need information
back … feedback … motivates people slightly more; it's a very good thing
to do. [P4, I]</p></disp-quote></p>
              </sec>
              <sec id="section2P-17423953211060253">
                <title>Physical and cognitive abilities</title>
                <p>Most participants reported losing physical abilities due to melanoma treatment.
They reported that this loss of mobility led to inability to effectively carry
out self-care and access health services on their own. They reported being
unable to leave the house, walk or carry out tasks.</p>
                <p>Those with visual, hearing or cognitive difficulties struggled with logistical
work such as organising and remembering to take their medication, and often
relied on others, for example, family members, to remind them. Several
participants reported having problems with their memory which caused them to
either forget to take their medication or to take the same medication twice.<disp-quote><p>I can forget things, or I’ll repeat things … I’ve taken my tablets twice
thinking, ‘Oh, I’ve not taken my tablets.’ … And I’ve just taken them
again quarter of an hour later. So, I have to be quite aware or else I
just might repeat [medication]. [P9, I]</p></disp-quote></p>
              </sec>
              <sec id="section2Q-17423953211060253">
                <title>Financial status</title>
                <p>All participants were receiving treatments under the NHS and most of their care
was free at the point of delivery. Those who were able to work, reported
suffering a reduction in income due to treatment side effects and were only able
to work part time. Some consequently struggled financially.<disp-quote><p>I’m a single woman with a mortgage, and when something like this happens
it's … you’ve got to try and get yourself sorted out … it's all right
when you’re working full-time, but when you have to go part-time. [P9,
I]</p></disp-quote></p>
              </sec>
              <sec id="section2R-17423953211060253">
                <title>Support network</title>
                <p>Participants reported gaining emotional and companionship support, reassurance
and help with decision-making from family, and were able to share information
with clinicians openly and comfortably.<disp-quote><p>I have to say I’ve been helped a lot by both my consultant and the
clinical nurse, who’ve been very good and very, helpful to me and
encouraging. [P3, I]</p></disp-quote></p>
                <p>Having understanding colleagues and employers was reported to be important as
participants had to take time off work to attend multiple hospital appointments
and recover from severe side effects. Furthermore, participants mentioned
experiencing loneliness and felt that they would benefit from emotional support
and interacting with other people with advanced melanoma.</p>
                <p>Participants stressed the need to encourage people living with cancer, taking
part in a trial, to seek mental health support and be provided with or
signposted to information sources and support groups.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="section3-17423953211060253">
              <title>Discussion</title>
              <p>To our knowledge, this is the first study to provide a detailed description of the
burdensome impacts of trial participation and elements of patient capacity that
could influence the burden experienced by patients with advanced melanoma taking
oral targeted combination therapy. This study reveals the extensive effort afforded
by patients entering a clinical trial including understanding their illness, the
treatments, trial documents and processes. Findings show that participants received
adequate amount of verbal and written information, and had easy access to
clinicians; however, knowledge gaps and misconceptions still existed. In addition,
the rationale for randomisation were poorly understood. These findings are in line
with the literature<sup><xref rid="bibr12-17423953211060253" ref-type="bibr">12</xref></sup> which also found therapeutic misconceptions, and
insufficient health and research literacy in patients with chronic illness. The
rationale for these findings include information overload at an emotional time and
failure to remember, understand or fully engage with trial information prior to
consenting to participate.<sup><xref rid="bibr12-17423953211060253" ref-type="bibr">12</xref></sup> Similar to our findings, evidence shows that treatment side
effects, for example, fatigue, contribute to emotional distress and mental health
problems among patients with cancer, potentially leading to inability to
work.<sup><xref rid="bibr27-17423953211060253" ref-type="bibr">27</xref></sup> Furthermore, up to 70% of patients with cancer stop working or
experience a reduction in work hours after being diagnosed or treated for cancer,
with negative implications for their income.<sup><xref rid="bibr27-17423953211060253" ref-type="bibr">27</xref></sup></p>
              <p>Participants in this study lived a considerable distance from hospitals, attended
multiple appointments for treatment and trial-related activities, and endured an
enormous burden associated with travel to attend appointments. This has cost
implications as out-of-pocket expenses for travel are not covered or
reimbursed.<sup><xref rid="bibr28-17423953211060253" ref-type="bibr">28</xref></sup> The high burden of trial participation in clinical trials
has been identified as a barrier to recruitment, retention and active engagement in
interventions.<sup><xref rid="bibr29-17423953211060253" ref-type="bibr">29</xref></sup> A recent systematic review<sup><xref rid="bibr12-17423953211060253" ref-type="bibr">12</xref></sup> found that the most common
reasons cited by people with cancer for declining participation, missing hospital
appointments and withdrawing from an ongoing trial, were complexity and stringency
of the study protocol, additional research procedures, appointments and travel time
to hospitals. These are important points of consideration because the success of
RCTs depend on their ability to recruit sufficient patients and to ensure that as
few patients as possible withdraw from the trial or become lost to follow-up.
Similar to our findings, the literature<sup><xref rid="bibr12-17423953211060253" ref-type="bibr">12</xref></sup> shows that aspects of the
trial process such as recruitment, randomisation and treatment allocation often
impose a psychological burden on research participants including disappointment,
anger and depression.</p>
              <p>Patients with advanced melanoma in this study experienced demanding treatment
workload with debilitating side effects. Participants obtained and administered oral
medication, monitored symptoms and self-managed side effects. In line with other
studies,<sup><xref rid="bibr26-17423953211060253" ref-type="bibr">26</xref>,<xref rid="bibr28-17423953211060253" ref-type="bibr">28</xref></sup> several participants in this study also took several
medications to control treatment side effects. Thus, the daily work that patients do
to manage their cancer is exacerbated by the additional effort to manage drug
interactions and side effects, all of which have to be integrated into their social,
work and family lives.<sup><xref rid="bibr28-17423953211060253" ref-type="bibr">28</xref></sup> Self-management practices represent a significant burden
for patients despite being seen as a solution to the long-term management of chronic
illness by healthcare professionals and policy makers,<sup><xref rid="bibr7-17423953211060253" ref-type="bibr">7</xref>,<xref rid="bibr11-17423953211060253" ref-type="bibr">11</xref>,<xref rid="bibr26-17423953211060253" ref-type="bibr">26</xref></sup> as the resources to achieve
these ends may not be available to the patient.<sup><xref rid="bibr7-17423953211060253" ref-type="bibr">7</xref></sup> Participants in this study
highlighted several factors that they felt affected the burdens they experienced
including altruistic motivation, emotion-focused coping, personal attributes and
skills, physical and cognitive abilities and support network. These are resources
that may counteract the negative impact of excessive demand of healthcare, lessen
the treatment burden and influence adherence and engagement with
clinicians.<sup><xref rid="bibr7-17423953211060253" ref-type="bibr">7</xref>,<xref rid="bibr30-17423953211060253" ref-type="bibr">30</xref></sup> Hence, it is vital that clinicians assess and assist with areas
in which patients may need extra support and guidance, and consider patients’
capacity to undertake healthcare workload.<sup><xref rid="bibr13-17423953211060253" ref-type="bibr">13</xref>,<xref rid="bibr28-17423953211060253" ref-type="bibr">28</xref></sup> It is also vital that trials
consider patient burden and capacity as study variables.</p>
              <p>The findings also show that participants drew upon a range of personal and social
resources to help them manage and cope with the demands of research participation.
For example, in line with the literature, emotion-focused coping such as focussing
on other life priorities, could help to manage negative emotions arising from the
burdensome work of self-care.<sup><xref rid="bibr30-17423953211060253" ref-type="bibr">30</xref></sup> Also, altruistic motivation,
maintaining a positive attitude and support from social network, employers and
clinicians could bolster a sense of positive psychological wellbeing and adherence
to self-care regimens.<sup><xref rid="bibr12-17423953211060253" ref-type="bibr">12</xref>,<xref rid="bibr13-17423953211060253" ref-type="bibr">13</xref>,<xref rid="bibr30-17423953211060253" ref-type="bibr">30</xref>,<xref rid="bibr31-17423953211060253" ref-type="bibr">31</xref></sup> The literature supports the use of social comparison as a means
of adapting to stressful circumstances.<sup><xref rid="bibr30-17423953211060253" ref-type="bibr">30</xref></sup> Participants also identified
positive reinforcement and feedback in research studies as enabling factors, in line
with the literature.<sup><xref rid="bibr12-17423953211060253" ref-type="bibr">12</xref></sup> These findings underscore the need to encourage patients to
acknowledge their burdens and communicate what could be done to better support
them.<sup><xref rid="bibr32-17423953211060253" ref-type="bibr">32</xref></sup></p>
              <sec id="section3A-17423953211060253">
                <title>Considerations for future trials to minimise participant burden</title>
                <p>Patients and members of the public should be involved at the planning stage of a
trial. Drawing on their experiential knowledge and ideas will ensure that
burdens are identified early and either eliminated or strategies are put in
place to minimise their effect.</p>
                <p>Clinicians and researchers should assess and carefully consider the difficulties
and challenges that patients will experience from therapeutic commitments and
trial participation. Consideration should also be given to capacity to manage
burden. The standard care clinical burden that patients already face need to be
determined and balanced against the demands of the trial in order to determine
whether they can realistically participate.<sup><xref rid="bibr29-17423953211060253" ref-type="bibr">29</xref></sup></p>
                <p>Education, guidance and support should be provided on how patients can
effectively integrate taking medications into their daily lives, simplify the
regimen, increase adherence and manage side effects of treatment. The reliance
of patients on clinicians for advice and support creates an opportunity for
clinicians and patients to co-create a feasible and actionable plan that would
help maximise patient capacity. These discussions could elicit a more open
dialogue with patients about how they are coping with their illness, treatment
and research participation, and how they can be assisted in areas where they may
need extra support and guidance. Toolkits to aid discussion include goal
elicitation, instrument for patient capacity assessment, workload assessments
and medication therapy management tools.<sup><xref rid="bibr8-17423953211060253" ref-type="bibr">8</xref></sup> Patients should also be
signposted to financial and mental health support resources.</p>
                <p>The process of seeking informed consent in trials contributes to psychological
burden, particularly where patients are told about the potential benefits of a
new treatment and then informed that their treatment allocation would be
determined by randomisation.<sup><xref rid="bibr6-17423953211060253" ref-type="bibr">6</xref>,<xref rid="bibr33-17423953211060253" ref-type="bibr">33</xref></sup> A clear explanation of
true equipoise and the rationale for randomisation could reduce this burden.
Furthermore, research burden is not sufficiently considered by regulatory
agencies which focus more on the risks of the intervention and data
collection.<sup><xref rid="bibr8-17423953211060253" ref-type="bibr">8</xref></sup> Shifting the focus to ensure protocols meet ethical
standards whilst imposing the smallest possible burden to effectively answer
research questions is paramount.</p>
                <p>One study showed that the median number of items collected per participant in a
sample of cancer RCTs was 599, but only 18% of the collected data was used and
reported.<sup><xref rid="bibr24-17423953211060253" ref-type="bibr">24</xref></sup> Researchers are urged to include only essential
items.<sup><xref rid="bibr34-17423953211060253" ref-type="bibr">34</xref></sup> Furthermore, using electronic questionnaires and
scheduling several activities for the same day, for example, consenting patients
in clinic during wait times and collecting data at the same visit, could
minimise number of patient visits to hospitals, interruptions to daily routine
and work, as well as minimising parking issues and other burdens.<sup><xref rid="bibr35-17423953211060253" ref-type="bibr">35</xref></sup></p>
              </sec>
              <sec id="section3B-17423953211060253">
                <title>Strengths and limitations of the study</title>
                <p>This study examined the burden of research participation experienced by patients
with advanced melanoma taking part in a clinical trial, and factors that may
affect their capacity to cope with these burdens. Although the sample size is
small, the study obtained rich information about participants’ experiences.
However, this study used a convenient sample of patients who volunteered their
time and provided self-reports of their experiences and it is possible that the
most burdened patients declined to be interviewed due to time constraints or
severity of illness. The factors affecting patient capacity discussed here were
based on participants’ account and further research is needed to examine their
possible role in influencing capacity to manage burden of research
participation. In addition, NPT appears to offer a robust conceptual framework
for understanding overall burden of research participation, although in line
with another qualitative study,<sup><xref rid="bibr11-17423953211060253" ref-type="bibr">11</xref></sup> psychological burden fell
outside the NPT framework. Nevertheless, by combining inductive and deductive
analyses, the emotional aspects of participants’ experiences were captured.</p>
              </sec>
            </sec>
            <sec id="section4-17423953211060253">
              <title>Conclusion</title>
              <p>This study provides a detailed description of burdens experienced by patients with
advanced melanoma in a clinical trial and elucidates factors that may lessen or
worsen the burden. Clearly, the burden of research participation for chronically ill
patients is a significant issue and will become even more pronounced with the
projected rise of cancer survivors in the UK and around the world. The consideration
of burdens during the planning and design of RCTs could help improve their conduct,
recruitment and retention as many of the burdens can be anticipated and avoided in a
move towards minimally disruptive research.</p>
            </sec>
            <sec sec-type="supplementary-material" specific-use="figshare">
              <title>Supplemental Material</title>
              <supplementary-material id="supp1-17423953211060253" position="float" content-type="local-data">
                <caption>
                  <title>sj-docx-1-chi-10.1177_17423953211060253 - Supplemental material for
Burden of cancer trial participation: A qualitative sub-study of the INTERIM
feasibility RCT</title>
                </caption>
                <media xlink:href="sj-docx-1-chi-10.1177_17423953211060253.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-docx-1-chi-10.1177_17423953211060253 for Burden of
cancer trial participation: A qualitative sub-study of the INTERIM feasibility
RCT by Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin
Jenkinson, Mark Middleton and Rubeta Matin in Chronic Illness</p>
              </supplementary-material>
              <supplementary-material id="supp2-17423953211060253" position="float" content-type="local-data">
                <caption>
                  <title>sj-docx-2-chi-10.1177_17423953211060253 - Supplemental material for
Burden of cancer trial participation: A qualitative sub-study of the INTERIM
feasibility RCT</title>
                </caption>
                <media xlink:href="sj-docx-2-chi-10.1177_17423953211060253.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-docx-2-chi-10.1177_17423953211060253 for Burden of
cancer trial participation: A qualitative sub-study of the INTERIM feasibility
RCT by Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin
Jenkinson, Mark Middleton and Rubeta Matin in Chronic Illness</p>
              </supplementary-material>
              <supplementary-material id="supp3-17423953211060253" position="float" content-type="local-data">
                <caption>
                  <title>sj-docx-3-chi-10.1177_17423953211060253 - Supplemental material for
Burden of cancer trial participation: A qualitative sub-study of the INTERIM
feasibility RCT</title>
                </caption>
                <media xlink:href="sj-docx-3-chi-10.1177_17423953211060253.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-docx-3-chi-10.1177_17423953211060253 for Burden of
cancer trial participation: A qualitative sub-study of the INTERIM feasibility
RCT by Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin
Jenkinson, Mark Middleton and Rubeta Matin in Chronic Illness</p>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgements</title>
              <p>The authors would like to thank the participants with advanced melanoma for taking
part in the study, the clinical staff at participating NHS hospitals who recruited
participants and the INTERIM clinical trial management group, Cambridge Clinical
Trials Unit – Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, for
their support. We would also like to thank the NIHR Biomedical Research Centre in
Oxford and NIHR Collaboration for Leadership in Applied Health Research and Care
(CLAHRC) Oxford, now recommissioned as NIHR Applied Research Collaboration (ARC)
Oxford and Thames Valley at Oxford Health NHS Foundation Trust for their
support.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributorship:</bold> PC, MM, CJ, RF, AG and RM conceived the study, developed the study protocol and
obtained ethical approval. CN researched the literature and was responsible for
patient recruitment. RF and CN were involved in data analysis. CN wrote the
first draft of the manuscript. All authors reviewed and edited the manuscript
and approved the final version of the manuscript.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p>The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Ethical approval (<italic toggle="yes">include full name of committee approving the
research and if available mention reference number of that
approval</italic>):</bold> Ethical opinion was obtained from Cambridge South Research Ethics Committee
[17/EE/0340]. The trial was also reviewed by the Medicines and Healthcare
Products Regulatory Agency (MHRA; reference: 2016-005228-27).</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by the National Institute for Health Research (NIHR) Research for
Patient Benefit (RfPB) (Grant Reference Number: PB-PG-0815-20048). The views
expressed are those of the author(s) and not necessarily those of the NIHR or
the Department of Health and Social Care.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Informed consent:</bold> Written informed consent was obtained from all subjects before the study.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>ORCID iDs:</bold> Chidiebere Nwolise <ext-link xlink:href="https://orcid.org/0000-0002-5510-1103" ext-link-type="uri">https://orcid.org/0000-0002-5510-1103</ext-link></p>
                <p>Crispin Jenkinson <ext-link xlink:href="https://orcid.org/0000-0002-3692-0779" ext-link-type="uri">https://orcid.org/0000-0002-3692-0779</ext-link></p>
                <p>Rubeta Matin <ext-link xlink:href="https://orcid.org/0000-0002-9695-5412" ext-link-type="uri">https://orcid.org/0000-0002-9695-5412</ext-link></p>
              </fn>
              <fn fn-type="other">
                <p><bold>Trial registration <italic toggle="yes">(where applicable)</italic>:</bold> EU Clinical Trials Register; 2016-005228-27.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bibr1-17423953211060253">
                <label>1</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>NH</given-names></name><name><surname>Li</surname><given-names>WQ</given-names></name><name><surname>Qureshi</surname><given-names>AA</given-names></name></person-group>, <etal>et al.</etal><comment><italic toggle="yes">Epidemiology of melanoma. In: Cutaneous Melanoma: Etiology and
Therapy [Internet]</italic></comment>, <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK481862/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK481862/</ext-link> (<comment>2017,
accessed 11 May 2020</comment>).</mixed-citation>
              </ref>
              <ref id="bibr2-17423953211060253">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>Z</given-names></name><name><surname>Yousaf</surname><given-names>N</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name></person-group>. <article-title>Melanoma epidemiology, biology and
prognosis</article-title>. <source>EJC Suppl</source><year>2013</year>; <volume>11</volume>:
<fpage>81</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">26217116</pub-id></mixed-citation>
              </ref>
              <ref id="bibr3-17423953211060253">
                <label>3</label>
                <mixed-citation publication-type="other"><collab>Melanoma UK</collab>. <comment>2020
Melanoma Skin Cancer Report: stemming the global epidemic</comment>,
<ext-link xlink:href="https://www.melanomauk.org.uk/Handlers/Download.ashx?IDMF=91e70826-91d1-4b5e-9b0c-3dd3da10686d" ext-link-type="uri">https://www.melanomauk.org.uk/Handlers/Download.ashx?IDMF=91e70826-91d1-4b5e-9b0c-3dd3da10686d</ext-link>
(<year>2020</year>, <comment>accessed 22 July
2021</comment>).</mixed-citation>
              </ref>
              <ref id="bibr4-17423953211060253">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name></person-group>, <etal>et al.</etal><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries</article-title>.
<source>CA Cancer J Clin</source><year>2018</year>; <volume>68</volume>:
<fpage>394</fpage>–<lpage>424</lpage>.<pub-id pub-id-type="pmid">30207593</pub-id></mixed-citation>
              </ref>
              <ref id="bibr5-17423953211060253">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Grob</surname><given-names>JJ</given-names></name><name><surname>Stroyakovskiy</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>Five-year outcomes with dabrafenib plus trametinib in metastatic
melanoma</article-title>. <source>N Engl J Med</source><year>2019</year>; <volume>381</volume>:
<fpage>626</fpage>–<lpage>636</lpage>.<pub-id pub-id-type="pmid">31166680</pub-id></mixed-citation>
              </ref>
              <ref id="bibr6-17423953211060253">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Given</surname><given-names>BA</given-names></name><name><surname>Given</surname><given-names>CW</given-names></name><name><surname>Sikorskii</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Medication burden of treatment using oral cancer
medications</article-title>. <source>Asia Pac J Oncol Nurs</source><year>2017</year>; <volume>4</volume>:
<fpage>275</fpage>–<lpage>282</lpage>.<pub-id pub-id-type="pmid">28966954</pub-id></mixed-citation>
              </ref>
              <ref id="bibr7-17423953211060253">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May</surname><given-names>CR</given-names></name><name><surname>Eton</surname><given-names>DT</given-names></name><name><surname>Boehmer</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Rethinking the patient: using burden of treatment theory to
understand the changing dynamics of illness</article-title>. <source>BMC
Health Serv Res</source><year>2014</year>; <volume>14</volume>: <fpage>281</fpage>.<pub-id pub-id-type="pmid">24969758</pub-id></mixed-citation>
              </ref>
              <ref id="bibr8-17423953211060253">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dabrh AM</surname><given-names>A</given-names></name><name><surname>Gallacher</surname><given-names>K</given-names></name><name><surname>Boehmer</surname><given-names>KR</given-names></name></person-group>, <etal>et al.</etal><article-title>Minimally disruptive medicine: the evidence and conceptual
progress supporting a new era of healthcare</article-title>. <source>J R
Coll Physicians Edinb</source><year>2015</year>; <volume>45</volume>:
<fpage>114</fpage>–<lpage>117</lpage>.<pub-id pub-id-type="pmid">26181525</pub-id></mixed-citation>
              </ref>
              <ref id="bibr9-17423953211060253">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eton</surname><given-names>DT</given-names></name><name><surname>Ramalho de Oliveira</surname><given-names>D</given-names></name><name><surname>Egginton</surname><given-names>JS</given-names></name></person-group>, <etal>et al.</etal><article-title>Building a measurement framework of burden of treatment in
complex patients with chronic conditions: a qualitative
study</article-title>. <source>Patient Relat Outcome Meas</source><year>2012</year>; <volume>3</volume>:
<fpage>39</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">23185121</pub-id></mixed-citation>
              </ref>
              <ref id="bibr10-17423953211060253">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallacher</surname><given-names>KI</given-names></name><name><surname>Quinn</surname><given-names>T</given-names></name><name><surname>Kidd</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Systematic review of patient-reported measures of treatment
burden in stroke</article-title>. <source>BMJ Open</source><year>2019</year>; <volume>9</volume>: <fpage>e029258</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr11-17423953211060253">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallacher</surname><given-names>K</given-names></name><name><surname>May</surname><given-names>CR</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name></person-group>, <etal>et al.</etal><article-title>Understanding patients’ experiences of treatment burden in
chronic heart failure using normalization process theory</article-title>.
<source>Ann Fam Med</source><year>2011</year>; <volume>9</volume>:
<fpage>235</fpage>–<lpage>243</lpage>.<pub-id pub-id-type="pmid">21555751</pub-id></mixed-citation>
              </ref>
              <ref id="bibr12-17423953211060253">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naidoo</surname><given-names>N</given-names></name><name><surname>Nguyen</surname><given-names>VT</given-names></name><name><surname>Ravaud</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>The research burden of randomized controlled trial participation:
a systematic thematic synthesis of qualitative evidence</article-title>.
<source>BMC Med</source><year>2020</year>; <volume>18</volume>: <fpage>6</fpage>.<pub-id pub-id-type="pmid">31955710</pub-id></mixed-citation>
              </ref>
              <ref id="bibr13-17423953211060253">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallacher</surname><given-names>KI</given-names></name><name><surname>May</surname><given-names>CR</given-names></name><name><surname>Langhorne</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal><article-title>A conceptual model of treatment burden and patient capacity in
stroke</article-title>. <source>BMC Fam Pract</source><year>2018</year>; <volume>19</volume>: <fpage>9</fpage>.<pub-id pub-id-type="pmid">29316892</pub-id></mixed-citation>
              </ref>
              <ref id="bibr14-17423953211060253">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippiett</surname><given-names>KA</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Myall</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Patients and informal caregivers’ experiences of burden of
treatment in lung cancer and chronic obstructive pulmonary disease (COPD): a
systematic review and synthesis of qualitative research</article-title>.
<source>BMJ Open</source><year>2019</year>; <volume>9</volume>: <fpage>e020515</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr15-17423953211060253">
                <label>15</label>
                <mixed-citation publication-type="other"><collab>The National Institute for Health
and Care Excellence (NICE)</collab>. <comment>Trametinib in combination with
dabrafenib for treating unresectable or metastatic melanoma</comment>,
<ext-link xlink:href="https://www.nice.org.uk/guidance/ta396/chapter/3-evidence" ext-link-type="uri">https://www.nice.org.uk/guidance/ta396/chapter/3-evidence</ext-link>
(<year>2016</year>, <comment>accessed 05 May
2020</comment>).</mixed-citation>
              </ref>
              <ref id="bibr16-17423953211060253">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Cameron</surname><given-names>MC</given-names></name><name><surname>Garden</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>A systematic review of patient-reported outcome instruments of
dermatologic adverse events associated with targeted cancer
therapies</article-title>. <source>Support Care Cancer</source><comment><italic toggle="yes">2015</italic></comment>; <volume>23</volume>:
<fpage>2231</fpage>–<lpage>2244</lpage>.<pub-id pub-id-type="pmid">25564221</pub-id></mixed-citation>
              </ref>
              <ref id="bibr17-17423953211060253">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Maio</surname><given-names>M</given-names></name><name><surname>Basch</surname><given-names>E</given-names></name><name><surname>Bryce</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Patient-reported outcomes in the evaluation of toxicity of
anticancer treatments</article-title>. <source>Nat Rev Clin Oncol</source><year>2016</year>; <volume>13</volume>: <fpage>319</fpage>.<pub-id pub-id-type="pmid">26787278</pub-id></mixed-citation>
              </ref>
              <ref id="bibr18-17423953211060253">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basch</surname><given-names>E</given-names></name></person-group>. <article-title>The missing voice of patients in
drug-safety reporting</article-title>. <source>N Engl J Med</source><year>2010</year>; <volume>362</volume>:
<fpage>865</fpage>–<lpage>869</lpage>.<pub-id pub-id-type="pmid">20220181</pub-id></mixed-citation>
              </ref>
              <ref id="bibr19-17423953211060253">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>The development of the Australian national palliative care
clinical studies collaborative “integrating qualitative research into
clinical trials framework”</article-title>. <source>J Palliat Med</source><year>2021</year>; <volume>24</volume>:
<fpage>331</fpage>–<lpage>337</lpage>.<pub-id pub-id-type="pmid">33085551</pub-id></mixed-citation>
              </ref>
              <ref id="bibr20-17423953211060253">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrie</surname><given-names>P</given-names></name><name><surname>Matin</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>A randomised phase II feasibility study of intermittent versus
continuous dosing of targeted therapy in patients with BRAFV600 mutant
advanced melanoma (INTERIM)</article-title>. <source>Ann Oncol</source><year>2018</year>; <volume>29</volume>: <fpage>viii464</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr21-17423953211060253">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>A</given-names></name><name><surname>Sainsbury</surname><given-names>P</given-names></name><name><surname>Craig</surname><given-names>J</given-names></name></person-group>. <article-title>Consolidated criteria for reporting
qualitative research (COREQ): a 32-item checklist for interviews and focus
groups</article-title>. <source>Int J Qual Health Care</source><year>2007</year>; <volume>19</volume>:
<fpage>349</fpage>–<lpage>357</lpage>.<pub-id pub-id-type="pmid">17872937</pub-id></mixed-citation>
              </ref>
              <ref id="bibr22-17423953211060253">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maloney</surname><given-names>C</given-names></name><name><surname>Lyons</surname><given-names>KD</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group>, <etal>et al.</etal><article-title>Patient perspectives on participation in the ENABLE II randomized
controlled trial of a concurrent oncology palliative care intervention:
benefits and burdens</article-title>. <source>Palliat Med</source><year>2013</year>; <volume>27</volume>:
<fpage>375</fpage>–<lpage>383</lpage>.<pub-id pub-id-type="pmid">22573470</pub-id></mixed-citation>
              </ref>
              <ref id="bibr23-17423953211060253">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain-Gambles</surname><given-names>M</given-names></name></person-group>. <article-title>South Asian patients’ views and
experiences of clinical trial participation</article-title>. <source>Fam
Pract</source><year>2004</year>; <volume>21</volume>:
<fpage>636</fpage>–<lpage>642</lpage>.<pub-id pub-id-type="pmid">15528290</pub-id></mixed-citation>
              </ref>
              <ref id="bibr24-17423953211060253">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gale</surname><given-names>NK</given-names></name><name><surname>Heath</surname><given-names>G</given-names></name><name><surname>Cameron</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>Using the framework method for the analysis of qualitative data
in multi-disciplinary health research</article-title>. <source>BMC Med Res
Methodol</source><year>2013</year>; <volume>13</volume>: <fpage>117</fpage>.<pub-id pub-id-type="pmid">24047204</pub-id></mixed-citation>
              </ref>
              <ref id="bibr25-17423953211060253">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May</surname><given-names>C</given-names></name><name><surname>Finch</surname><given-names>T</given-names></name></person-group>. <article-title>Implementing, embedding, and
integrating practices: an outline of normalization process
theory</article-title>. <source>Sociology</source><year>2009</year>; <volume>43</volume>:
<fpage>535</fpage>–<lpage>554</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr26-17423953211060253">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>LS</given-names></name><name><surname>Vest</surname><given-names>BM</given-names></name><name><surname>Madurai</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Chronic kidney disease (CKD) treatment burden among low-income
primary care patients</article-title>. <source>Chronic Illn</source><year>2015</year>; <volume>11</volume>:
<fpage>171</fpage>–<lpage>183</lpage>.<pub-id pub-id-type="pmid">25416418</pub-id></mixed-citation>
              </ref>
              <ref id="bibr27-17423953211060253">
                <label>27</label>
                <mixed-citation publication-type="book"><collab>Institute of Medicine (US) Committee
on Psychosocial Services to Cancer Patients/Families in a Community
Setting</collab>. <article-title>The psychosocial needs of cancer patients.
In: </article-title><source>Cancer care for the whole patient: Meeting
psychosocial health needs</source>. <publisher-loc>Washington
(DC)</publisher-loc>: <publisher-name>National Academies Press
(US)</publisher-name>, 1-36. <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK4011/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK4011/</ext-link> (<year>2008</year>,
<comment>accessed 05 May 2020</comment>).</mixed-citation>
              </ref>
              <ref id="bibr28-17423953211060253">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sav</surname><given-names>A</given-names></name><name><surname>Kendall</surname><given-names>E</given-names></name><name><surname>McMillan</surname><given-names>SS</given-names></name></person-group>, <etal>et al.</etal><article-title>‘You say treatment, I say hard work’: treatment burden among
people with chronic illness and their carers in Australia</article-title>.
<source>Health Soc Care Community</source><year>2013</year>; <volume>21</volume>:
<fpage>665</fpage>–<lpage>674</lpage>.<pub-id pub-id-type="pmid">23701664</pub-id></mixed-citation>
              </ref>
              <ref id="bibr29-17423953211060253">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Given</surname><given-names>BA</given-names></name><name><surname>Given</surname><given-names>CW</given-names></name><name><surname>Vachon</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>Do we have a clue: the treatment burden for the patient With
cancer?</article-title><source>Cancer Nurs</source><year>2016</year>; <volume>39</volume>: <fpage>423</fpage>.<pub-id pub-id-type="pmid">27542146</pub-id></mixed-citation>
              </ref>
              <ref id="bibr30-17423953211060253">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridgeway</surname><given-names>JL</given-names></name><name><surname>Egginton</surname><given-names>JS</given-names></name><name><surname>Tiedje</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Factors that lessen the burden of treatment in complex patients
with chronic conditions: a qualitative study</article-title>.
<source>Patient Prefer Adherence</source><year>2014</year>; <volume>8</volume>: <fpage>339</fpage>.<pub-id pub-id-type="pmid">24672228</pub-id></mixed-citation>
              </ref>
              <ref id="bibr31-17423953211060253">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>S</given-names></name><name><surname>Greer</surname><given-names>S</given-names></name></person-group>. <article-title>Promoting psychological well-being in
the face of serious illness: when theory, research and practice inform each
other</article-title>. <source>Psychooncology</source><year>2000</year>; <volume>9</volume>:
<fpage>11</fpage>–<lpage>19</lpage>.<pub-id pub-id-type="pmid">10668055</pub-id></mixed-citation>
              </ref>
              <ref id="bibr32-17423953211060253">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>OC</given-names></name><name><surname>Leff</surname><given-names>B</given-names></name><name><surname>Ritchie</surname><given-names>CS</given-names></name></person-group>, <etal>et al.</etal><article-title>A systematic literature review of the assessment of treatment
burden experienced by patients and their caregivers</article-title>.
<source>BMC Geriatr</source><year>2019</year>; <volume>19</volume>: <fpage>262</fpage>.<pub-id pub-id-type="pmid">31604424</pub-id></mixed-citation>
              </ref>
              <ref id="bibr33-17423953211060253">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobias</surname><given-names>JS</given-names></name><name><surname>Souhami</surname><given-names>RL</given-names></name></person-group>. <article-title>Fully informed consent can be
needlessly cruel</article-title>. <source>Br Med J</source><year>1993</year>; <volume>307</volume>:
<fpage>1199</fpage>–<lpage>1201</lpage>.<pub-id pub-id-type="pmid">8135933</pub-id></mixed-citation>
              </ref>
              <ref id="bibr34-17423953211060253">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Leary</surname><given-names>E</given-names></name><name><surname>Seow</surname><given-names>H</given-names></name><name><surname>Julian</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Data collection in cancer clinical trials: too much of a good
thing?</article-title><source>Clin Trials</source><year>2013</year>; <volume>10</volume>:
<fpage>624</fpage>–<lpage>632</lpage>.<pub-id pub-id-type="pmid">23785066</pub-id></mixed-citation>
              </ref>
              <ref id="bibr35-17423953211060253">
                <label>35</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Sara</surname><given-names>DM</given-names></name></person-group>. <comment>Minimally disruptive research: a respectful
approach to conducting clinical studies</comment>, <ext-link xlink:href="https://minimallydisruptivemedicine.org/2017/01/03/minimally-disruptive-research-a-respectful-approach-to-conducting-clinical-studies/" ext-link-type="uri">https://minimallydisruptivemedicine.org/2017/01/03/minimally-disruptive-research-a-respectful-approach-to-conducting-clinical-studies/</ext-link>
(<year>2017</year>, <comment>accessed 05 May
2020</comment>).</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
